Apretude

(cabotegravir, rilpivirine)

3 ML cabotegravir 200 MG/ML Injection [Apretude]

NO BLACK BOX WARNING

Dosage & administration

* Refer to full prescribing information for detailed information on dosage and administration recommendations.
* Prior to initiating treatment with CABENUVA, oral lead-in dosing may be considered to assess the tolerability of cabotegravir and rilpivirine with the recommended dosage used for approximately 1 month.
* For gluteal intramuscular injection only.
* Recommended Monthly Dosing Schedule: Initiate injections of CABENUVA (600 mg of cabotegravir and 900 mg of rilpivirine) on the last day of current antiretroviral therapy or oral lead-in and continue with injections of CABENUVA (400 mg of cabotegravir and 600 mg of rilpivirine) every month thereafter.
* Recommended Every-2-Month Dosing Schedule: Initiate injections of CABENUVA (600 mg of cabotegravir and 900 mg of rilpivirine) on the last day of current antiretroviral therapy or oral lead-in for 2 consecutive months and continue with injections of CABENUVA every 2 months thereafter.

drug label

Apretude prescribing information

Contact Medical Science Liaison Report Adverse Event

prior authorization

Apretude prior authorization resources

Most recent Apretude prior authorization forms

View By Payer

Updated: May 30, 2023Cigna - Cabenuva Prior Authorization Form

PDFComplete Letter of Medical Necessity

PDFPA Checklist

Learn More

Benefits investigation

PDFCabenuva Enrollment Form

Learn More

Reimbursement help (FRM)

OTHERReceive Assistance from an FRM Regarding Reimbursement Information

Learn More

pharmacy

Apretude preferred pharmacy

PDFPharmacy List

financial assistance

Apretude financial assistance options

Co-pay savings program

commercial only

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form

Foundation programs

under insured

no insurance

goverment insurance

65+

PDFCabenuva Enrollment Form

PDFCommon Patient Assistance Program Application (CPAPA) Companion Document

PDFCommon Patient Assistance Program Application (CPAPA)

Learn More

Overview

Charitable 501(c)(3) organizations provide direct cost-sharing and other support (e.g., travel, counseling) through disease-state funds to indigent patients on first-come first-served basis
These organizations may receive financial contributions from drug manaufacturers for particular disease-state funds that cannot provide funds directly to patients - the foundation must be independent/unaligned

Patient benefit

Patients apply for grants that cover a portion (or all) of their out-of-pocket costs (deductibles and co-pays) until the grant is exhausted

Patient eligibility

Patients must apply and meet eligibility criteria including income level (typically a multiple of federal poverty line), specific diagnosis, insurance status, etc.

How to sign up

Patients submit proof of out-of-pocket drug costs to charities for reimbursement

patient education

Apretude patient education

Getting started on Apretude

To share resource; ask patient to:

1.Pull out phone

2.Open camera

3.Scan QR code with camera

4.Tap link